Prodalim Expands Solos Technology Platform in the United States with New California Operations
13.4.2026 12:24:00 CEST | Business Wire | Press Release
Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its Solos platform in the United States with the launch of operations at a new facility in Hopland, California.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413385326/en/
Prodalim Expands Solos Technology Platform in the United States with New California Operations
The new site marks a key milestone in the continued globalization of Solos, Prodalim’s patented aroma recovery and beverage innovation platform, and positions Solos at the center of one of the world’s most important wine-producing regions, strengthening collaboration with leading beverage producers.
This expansion follows the recent inauguration of the Solos Iberia facility and joint ventures in Germany and Switzerland, further strengthening Solos’ global platform.
California accounts for more than 80% of U.S. wine production, with approximately 2.5 billion liters produced annually, making it a global hub for wine production and beverage innovation.
The Hopland facility has an initial processing capacity of approximately 15 million liters per year, with expansion potential in the near term.
With this addition, Prodalim now operates four sites in the United States, including its Winter Garden, Florida headquarters and juice solutions hub, a Specialty Ingredients & Solutions R&D and production center, and juice terminals in Port Elizabeth, New Jersey and South Gate, California.
Through the Solos platform, Prodalim applies proprietary technologies to recover and recreate natural aroma compounds from fermented beverages, enabling producers to enhance authenticity and preserve sensory quality across evolving beverage categories.
The new operations support collaboration with producers across the Northern California ecosystem, including Rack & Riddle Holdings, LLC, the largest custom sparkling wine producer in the United States.
As part of its recent transformation, Prodalim has reorganized its operations into three purpose-driven divisions:
Juice Solutions – a one-stop-shop for juice producers, covering sourcing, logistics, formulation and blending
Specialty Ingredients & Solutions – delivering taste and functional ingredients such as FTNF, flavors, essential oils, citrus fibers and natural colors, supported by in-house R&D
SOLOS – a premium, patent-based de-alcoholization platform serving the fast-growing NoLo segment
All divisions are supported by Prodalim’s vertically integrated, regenerative supply chain, anchored in circular economy principles, enabling customers to innovate with sustainability and performance at their core.
About Prodalim
Prodalim is a global leader in juice and specialty ingredients solutions, harnessing nature’s essence to craft healthier creations. With its plant-to-people supply chain and global footprint, the company develops sustainable, innovative solutions for the food and beverage industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260413385326/en/
Contacts
IR@prodalim.com
www.prodalim.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.prodalim.co
m&esheet=54496128&newsitemid=20260413385326&lan=en-US&anchor=www.prodalim.com&in
dex=1&md5=ca95a2832a06072c4c61234996950638
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom